News that a domestically developed obesity treatment has received product approval has drawn attention to business opportunities in the pharmaceutical and biotech sectors. The company’s self-developed long-acting treatment is being prepared for launch, laying the groundwork for turning research and development achievements into sales. The developer is also conducting clinical trials to expand the treatment’s use beyond obesity to other metabolic diseases. However, approval does not guarantee sales success, so supply schedules, pricing, and prescription demand need to be assessed. Since the developer and its holding company have different earnings structures, it is also worth examining how closely each company’s performance is tied to the treatment.


Those considering additional investments in the pharmaceutical and biotech sectors can assess both commercialization progress and the amount of investment required. Raising funds through a stock account may be an option, depending on the account held and the eligibility requirements for the stocks involved. Investors can also check whether existing securities credit or unsettled trades can be refinanced. Before using such financing, they should compare interest rates, fees, collateral maintenance requirements, and repayment obligations, while taking into account the potential strain on their accounts from share price fluctuations. A financing plan suited to their ability to repay can help them systematically assess business opportunities taking shape with the launch of new drugs.


Among the available options, All New Stock Loan is drawing interest with a range of interest rates and product offerings, including products with annual rates in the 5% range. It is reportedly being considered as an option by investors seeking greater flexibility in responding to investment opportunities amid rapidly changing market conditions.

Pharma Stocks Draw Interest After Homegrown Obesity Drug Approval... What Is the 4x Buying Strategy Ahead of Launch? View original image

◆ All New Stock Loan Launches Product with an Industry-Low Annual Rate in the 5% Range!

All New Stock Loan has launched a securities-linked credit product available at an industry-low annual rate in the 5% range, so investors can use a stock loan without undue burden. The product can be used both to purchase stocks and to refinance securities credit or unsettled trades. Investors can borrow up to four times their own capital, including that capital, regardless of their credit rating. Investors who use the alternative trading system (NXT) can also use the product.


Investors who would like to learn more about All New Stock Loan can contact its customer service center at 1599-8666 to speak with a professional adviser at any time, whether or not they qualify for a loan.


○ Product launched at an industry-low annual rate in the 5% range!

○ ETF trading available

○ Use up to four times your own capital for stock purchases! (including your own funds)

○ Same-day refinancing of securities credit or unsettled trades!

○ Trading available on the alternative trading system (NXT)

○ OK to buy stocks that were difficult to purchase using existing securities credit or stock loans!

* All New Stock Loan Customer Service Center: 1599-8666

Go to: https://allnewstockloan.co.kr


Samsung SDI, Alteogen, NAVER, HLB Pharmaceutical, LG Innotek



※ This content does not reflect the editorial direction of The Asia Business Daily. The information provider assumes all responsibility.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing